Leticia Oliveira-Ferrer

List of Publications by Year
in descending order

40 papers	1,525 citations	394421 19 h-index	315739 38 g-index
41 all docs	41 docs citations	41 times ranked	2702 citing authors

#	Article	IF	Citations
1	Circulating Cellular Communication Network Factor 1 Protein as a Sensitive Liquid Biopsy Marker for Early Detection of Breast Cancer. Clinical Chemistry, 2022, 68, 344-353.	3.2	5
2	Insights into the Steps of Breast Cancerâ€“Brain Metastases Development: Tumor Cell Interactions with the Bloodâ€“Brain Barrier. International Journal of Molecular Sciences, 2022, 23, 1900.	4.1	8
3	Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by Î³Î´ T Cells in Ovarian Cancer. Cells, 2022, 11, 964.	4.1	19
4	CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients. Clinical Epigenetics, 2021, 13, 15.	4.1	10
5	Molecular characteristics and tumorigenicity of ascitesâ€derived tumor cells: mitochondrial oxidative phosphorylation as a novel therapy target in ovarian cancer. Molecular Oncology, 2021, 15, 3578-3595.	4.6	14
6	p53 and p16 expression profiles in vulvar cancer: a translational analysis by the Arbeitsgemeinschaft GynÃkologische Onkologie Chemo and Radiotherapy in Epithelial Vulvar Cancer study group. American Journal of Obstetrics and Gynecology, 2021, 224, 595.e1-595.e11.	1.3	21
7	Molecular Mechanisms Associated with Brain Metastases in HER2-Positive and Triple Negative Breast Cancers. Cancers, 2021, 13, 4137.	3.7	22
8	BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer. Molecular Oncology, 2021, 15, 3615-3625.	4.6	8
9	Transcriptome Analysis in Vulvar Squamous Cell Cancer. Cancers, 2021, 13, 6372.	3.7	3
10	Clinical relevance of H-RAS, K-RAS, and N-RAS mRNA expression in primary breast cancer patients. Breast Cancer Research and Treatment, 2020, 179, 403-414.	2.5	16
11	Immunoglobulin G Subclass-Specific Glycosylation Changes in Primary Epithelial Ovarian Cancer. Frontiers in Immunology, 2020, 11, 654.	4.8	20
12	Genomic characterization of vulvar squamous cell carcinoma. Gynecologic Oncology, 2020, 158, 547-554.	1.4	21
13	ALCAM contributes to brain metastasis formation in non-small-cell lung cancer through interaction with the vascular endothelium. Neuro-Oncology, 2020, 22, 955-966.	1.2	36
14	Mechanisms of Tumor-Lymphatic Interactions in Invasive Breast and Prostate Carcinoma. International Journal of Molecular Sciences, 2020, 21, 602.	4.1	15
15	Tubulin Tyrosine Ligase Like 4 (TTLL4) overexpression in breast cancer cells is associated with brain metastasis and alters exosome biogenesis. Journal of Experimental and Clinical Cancer Research, 2020, 39, 205.	8.6	24
16	Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer. OncoImmunology, 2019, 8, e1674605.	4.6	59
17	Prognostic relevance of the Golgi mannosidase MAN1A1 in ovarian cancer: impact of N-glycosylation on tumour cell aggregation. British Journal of Cancer, 2019, 121, 944-953.	6.4	27
18	Immature O-glycans recognized by the macrophage glycoreceptor CLEC10A (MGL) are induced by 4-hydroxy-tamoxifen, oxidative stress and DNA-damage in breast cancer cells. Cell Communication and Signaling, 2019, 17, 107.	6.5	21

#	Article	IF	Citations
19	Interplay of lncRNA H19/miRâ€675 and lncRNA NEAT1/miRâ€204 in breast cancer. Molecular Oncology, 2019, 13, 1137-1149.	4.6	84
20	Reduced mannosidase MAN1A1 expression leads to aberrant N-glycosylation and impaired survival in breast cancer. British Journal of Cancer, 2018, 118, 847-856.	6.4	49
21	No need for NMDA receptor antibody screening in neurologically asymptomatic patients with ovarian teratomas. Journal of Neurology, 2018, 265, 431-432.	3.6	2
22	Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients. Scientific Reports, 2018, 8, 12974.	3.3	59
23	Prognostic Impact of CEACAM1 in Node-Negative Ovarian Cancer Patients. Disease Markers, 2018, 2018, 1-10.	1.3	8
24	Prognostic role of the sialyltransferase ST6GAL1 in ovarian cancer. Glycobiology, 2018, 28, 898-903.	2.5	37
25	Clinical relevance of cytoskeleton associated proteins for ovarian cancer. Journal of Cancer Research and Clinical Oncology, 2018, 144, 2195-2205.	2.5	35
26	Exosomal micro<scp>RNA</scp>s as tumor markers in epithelial ovarian cancer. Molecular Oncology, 2018, 12, 1935-1948.	4.6	125
27	Role of HYAL1 expression in primary breast cancer in the formation of brain metastases. Breast Cancer Research and Treatment, 2017, 162, 427-438.	2.5	10
28	Role of protein glycosylation in cancer metastasis. Seminars in Cancer Biology, 2017, 44, 141-152.	9.6	208
29	Selectin-independent adhesion during ovarian cancer metastasis. Biochimie, 2017, 142, 197-206.	2.6	25
30	Strong fascin expression promotes metastasis independent of its F-actin bundling activity. Oncotarget, 2017, 8, 110077-110091.	1.8	23
31	VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer patients. Oncotarget, 2017, 8, 43218-43227.	1.8	18
32	Loss of BRCA1 promotor hypermethylation in recurrent high-grade ovarian cancer. Oncotarget, 2017, 8, 83063-83074.	1.8	20
33	Breast cancer brain metastases: biology and new clinical perspectives. Breast Cancer Research, 2016, 18, 8.	5.0	226
34	E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer. British Journal of Cancer, 2016, 114, 213-220.	6.4	32
35	Relevance of Î²Galâ€“Î²GalNAc-containing glycans and the enzymes involved in their synthesis for invasion and survival in breast cancer patients. Breast Cancer Research and Treatment, 2015, 151, 515-528.	2.5	28
36	Cadherin-11 mRNA and protein expression in ovarian tumors of different malignancy: No evidence of oncogenic or tumor-suppressive function. Molecular and Clinical Oncology, 2015, 3, 1067-1072.	1.0	6

#	Article	IF	Citations
37	Prognostic relevance of glycosylation-associated genes in breast cancer. Breast Cancer Research and Treatment, 2014, 145, 295-305.	2.5	77
38	Combination therapy targeting integrins reduces glioblastoma tumor growth through antiangiogenic and direct antitumor activity and leads to activation of the pro-proliferative prolactin pathway. Molecular Cancer, 2013, 12, 144.	19.2	12
39	The metabolite 3-hydroxiglutaric acid effectively reduces glioblastoma growth in vivo by affecting the structural integrity of tumor vasculature. Cancer Letters, 2012, 326, 161-167.	7.2	3
40	Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway. Journal of Experimental and Clinical Cancer Research, 2008, 27, 86.	8.6	89